500+ leading experts from innovative biotechs, large pharma, academia and key service providers will be reuniting in Boston for 2023 to capitalize on recent success stories and collaborate over the most pressing industry challenges.
This is the only industry-led event dedicated to covering all challenges associated with potency for gene therapy drug developers specifically. We will unite with 60+ analytical, bioassay, Quality Control, regulatory and CMC experts to bring together content that gives actionable insights by combining both strategic and technical content.
Join this industry-focused meeting to get into the detail on selecting the most appropriate antibody assays to assess relative risk in different patients, dive deep into the latest understanding and mitigation strategies of the innate immune response, and analyze the best ways to predict and measure short and long-term immune responses to generate accurate safety profiles
At the interface between innovation in preclinical research and those at the forefront of clinical development lies the 4th Annual Gene Therapy for Ophthalmic Disorders Summit, uniting thought leaders from leading biopharma and academic institutes working to transform eye disease treatment.
Formulation and delivery experts are uniting to evaluate and optimize cutting edge delivery strategies including LNPs, AAVs, exosomes, peptide shuttles, and polymer nanoparticles at the Gene Editing Delivery Summit. Leverage this insight to supercharge precise and efficient extra-hepatic in vivo gene editing to patients with previously untreatable genetic diseases.
With a program co-authored by leading industry figures, over 3 days our 30+ expert speakers will present and share expertise in the following areas in Next-generation developments and therapeutic applications of CRISPR technologies and Innovative in vivo and ex vivo CRISPR delivery approaches
This summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products.
This summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights.
Join the meeting to accelerate the drug pipeline and revolutionize dry AMD treatment for millions of patients in the US and worldwide.
Join biopharma colleagues specializing in bioassays, molecular biology, physicochemical properties, quality, process development and regulation across 4 days of niche, expert presentations, and dedicated networking opportunities.
Don’t miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle.
